NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Oncotelic Therapeutics Opens Access to PDAOAI Evidence Interrogation Platform
TL;DR
Oncotelic Therapeutics' PDAOAI platform offers researchers a competitive edge by extracting meaningful biological signals from complex datasets without proprietary data training.
The PDAOAI platform works by analyzing large biomedical datasets and providing access to over 125,000 TGF beta abstracts through a dedicated Discord research channel.
This initiative accelerates cancer research, potentially improving treatment outcomes for patients with rare pediatric cancers and other serious diseases.
Oncotelic Therapeutics has opened access to an AI platform that analyzes biomedical data without training large language models on proprietary information.
Found this article helpful?
Share it with your network and spread the knowledge!
Oncotelic Therapeutics has opened research access to its proprietary PDAOAI evidence interrogation platform, which is designed to extract biologically meaningful signals from large and complex biomedical datasets without training bespoke large language models on proprietary data.
PDAOAI is an evidence interrogation platform that extracts biologically meaningful signals from large and complex biomedical datasets without requiring the training of bespoke large language models on proprietary data.
Oncotelic is providing researchers access to a comprehensive TGF beta literature corpus comprising more than 125,000 PubMed abstracts through a dedicated Discord research channel.
The platform was developed alongside Oncotelic's clinical and preclinical programs to enhance the speed, depth, and efficiency of discovery across its pipeline.
Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers.
Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (DIPG) through OT-101, melanoma through CA4P, and Acute Myeloid Leukemia (AML) through OXi 4503.
Oncotelic is developing AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder, and hypoactive sexual desire disorder, all of which affect large populations with unmet treatment needs.
The full press release is available at https://ibn.fm/U31jX, and the latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC.
BioMedWire is a specialized communications platform focused on developments in Biotechnology, Biomedical Sciences, and Life Sciences sectors, and is part of the Dynamic Brand Portfolio within IBN that distributes this type of content.
Curated from InvestorBrandNetwork (IBN)
